Member Info for beinthelead

This looks like a bad photoshop. If it wasn’t on this legitimate source, I’d have laughed it out of the room. Medusa brochure all over again :).

Mustang - That was pretty much what he said.

Let’s not do our best to curtail sharing here. Yes, the wait is frustrating. The research RAH has tabled is a legitimate assessment of what the evidence implies.

We all know the SP is moons away from where we think it should be.

Fully agree. And this is an important nod to what we can expect.

RAH, for balance, proof that is DOES cut it in human is what people are looking for here.

It’s clear for me, but the market needs proof.

CH - They won’t be cured, the treatment is not a ‘cure’ as such. Clear? Very difficult to say. The stage at which the patients entered the trial likely constrains that. But who knows - if the dosing is as targeted as we believe, and the efficacy is first class, there’s a chance.

The fact it’s safe whilst cleaving is enough to satisfy me.

In summary, news due in Q4 as discussed all day.

Absolutely Rip. Not even worthy of challenge.

They’re confusing escalation with expansion…

Q4. They need to talk.

Neutronic - I’ve backed out. Some discussions are worth leaving to others.

But still makes no sense?

We’re valuing the platform, as in the technology. As in, once they confirm the much works, we’ll be valued at a lot more.

Yes. At the point in 2021 where they likely had the PK data to proceed with Biopsies.

https://twitter.com/tom_the_bomb__/status/1595744029161193473?s=20&t=qnnUQASri-Cse_rBlkJtdQ

Isn’t it though. Just thinking that.

Another Gem Energy. Thanks.

Wild misunderstanding of the investment then.

That made no sense at all.

I could not care less who brings AVA to market. Foxconn make a load of cash making iPhones, but I’d rather be Apple.

Let’s get some data.

Way off the mark.

This is technology, not a piece of plastic. Huge lack of understanding.

Neutronic - most know the pathway to market.

“Theres a mountain in front of us before we sell anything.”

This discussion is about communicating the current status of the tech and attributing true value. We want an update. MoA confirmation and AVA on boots’ shelves will look after itself.

Nice.

And Apta has dropped 50%in the year, which suggests an element of ‘undervalued’ as our Affimer is. Apples for apples.

Yet no TR1s. Another good point to note.

Retire - Absolutely. Good point. Though happy for the cash to be in that asset.